$67.27 $1.74 (2.7%)

04:00 PM EST on 12/06/19

Arrowhead Pharmaceuticals Inc Com (NASDAQ:ARWR)

CAPS Rating: 3 out of 5

A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy.

Current Price $67.27 Mkt Cap $6.7B
Open $66.43 P/E Ratio 92.89
Prev. Close $65.53 Div. (Yield) $0.00 (0.0%)
Daily Range $65.70 - $69.00 Volume 1,966,633
52-Wk Range $11.67 - $73.72 Avg. Daily Vol. 2,184,851

Caps

How do you think NASDAQ:ARWR will perform against the market?

Add Stock to CAPS Watchlist

All Players

219 Outperform
19 Underperform
 

All-Star Players

44 Outperform
9 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top NASDAQ:ARWR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (69.72)
Submitted September 06, 2018

Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade,MarketWatch•September 6, 2018MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday,… More

NetscribeServcs (< 20)
Submitted February 19, 2007

“Arrow - Heading” downward.Arrowhead Research Corporation (Arrowhead) is a development stage nanotechnology company, commercializing technologies in the areas of life sciences, electronics and energy. Arrowhead operates four majority-owned… More

Recent Community Commentary

Read the most recent pitches from players about ARWR.

Recs

3
Member Avatar Bigsef77 (69.72) Submitted: 9/6/2018 11:23:29 AM : Outperform Start Price: $1.52 NASDAQ:ARWR Score: +4,293.92

Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade
,MarketWatch•September 6, 2018

MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday, after upbeat results of the company's treatment for chronic hepatitis B prompted an upgrade at B.

Recs

0
Member Avatar Quickcard (< 20) Submitted: 10/10/2017 5:07:56 PM : Outperform Start Price: $4.02 NASDAQ:ARWR Score: +1,549.67

Pharma companies with what are doing research with verifiable positive results in treatment for especially intractable medical conditions seem to be on a roll. I don't see this should not continue, especially as DNA/RNA research is reaching new highs at the same time.

Recs

1
Member Avatar motto1628 (62.80) Submitted: 10/4/2015 2:59:52 AM : Outperform Start Price: $5.99 NASDAQ:ARWR Score: +962.78

Functional cure for Hep B

Leaderboard

Find the members with the highest scoring picks in ARWR.

Score Leader

mistermiranga

mistermiranga (99.80) Score: +4,542.67

The Score Leader is the player with the highest score across all their picks in ARWR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mistermiranga 99.80 12/1/2016 Outperform 5Y $1.41 +4,687.90% +43.06% +4,644.85 0 Comment
Bigsef77 69.72 4/25/2017 5/9/2018 Outperform 3Y $1.52 +4,325.95% +32.03% +4,293.92 1 Comment
KidJones 34.06 4/22/2013 Outperform 5Y $1.78 +3,679.21% +102.11% +3,577.10 0 Comment
whoodatstockhot 87.12 7/8/2013 Outperform 5Y $2.02 +3,230.20% +92.15% +3,138.05 0 Comment
EvilEmpire 31.63 2/28/2013 Outperform 5Y $2.20 +2,957.73% +107.27% +2,850.45 0 Comment
MFBurritoSquat 96.26 12/19/2012 Outperform 3M $2.23 +2,916.59% +116.35% +2,800.24 0 Comment
hayrettin 70.82 8/24/2017 Outperform 5Y $2.50 +2,596.19% +28.75% +2,567.44 0 Comment
AJL7 < 20 2/3/2016 Outperform 5Y $3.26 +1,963.50% +64.49% +1,899.01 0 Comment
beecha < 20 9/19/2017 Outperform 5Y $3.35 +1,908.06% +25.94% +1,882.12 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Under5 < 20 9/13/2017 Outperform 5Y $3.42 +1,869.84% +25.96% +1,843.88 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ARWR.